MDT-AP-0426
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 95.52
- os_event
- true
- age_years
- 6.8
- sex
- F
- new_clusters
- C4
- umap1_2d
- 2.952986768
- umap2_2d
- 4.373597809
- umap1_3d
- 0.65547238
- umap2_3d
- -0.531189079
- umap3_3d
- -1.976295805
- dataset
- Med-Taylor
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG715 | — | — | 0.872 |
| 2 | MNG1082 | — | — | 0.869 |
| 3 | BS_74FS6GMW | ATRT | — | 0.849 |
| 4 | MNG926 | — | — | 0.848 |
| 5 | MNG592 | — | — | 0.842 |
| 6 | MDT-AP-1377 | Med | Medulloblastoma | 0.831 |
| 7 | SRR10842352 | — | — | 0.830 |
| 8 | SRR4296106 | — | cohortSQ1 | 0.830 |
| 9 | MNG883 | — | — | 0.828 |
| 10 | TCGA-43-A56V-01A-11R-A26W-07 | — | cohortSQ1 | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.650 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |